We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

High Dose Nimodipine Treatment Adjunct - 1

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00000332
First Posted: September 21, 1999
Last Update Posted: February 24, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Washington D.C. Veterans Affairs Medical Center
Information provided by:
National Institute on Drug Abuse (NIDA)
  Purpose
The purpose of this study is to determine if nimodipine is more effective than placebo in reducing stimulated craving for cocaine in cocaine dependent individuals denied access to cocaine in inpatient unit.

Condition Intervention Phase
Cocaine-Related Disorders Drug: Nimodipine Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: High Dose Nimodipine Pharmacotherapy Adjunct

Resource links provided by NLM:


Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Stimulated and non-stimulated craving
  • Stimulated and non-stimulated withdrawal
  • Anxiety, depression
  • Heart rate

Estimated Enrollment: 0
Actual Study Start Date: May 1998
Study Completion Date: April 2000
Primary Completion Date: January 2000 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   22 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
Please contact site for information.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000332


Locations
United States, District of Columbia
Washington DC VA
Washington, District of Columbia, United States, 20422
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
Washington D.C. Veterans Affairs Medical Center
Investigators
Principal Investigator: Steven Deutsch, M.D. Washington D.C. Veterans Affairs Medical Center
  More Information

ClinicalTrials.gov Identifier: NCT00000332     History of Changes
Other Study ID Numbers: NIDA-3-0009-1
Y01-3-0009-1
First Submitted: September 20, 1999
First Posted: September 21, 1999
Last Update Posted: February 24, 2017
Last Verified: December 2002

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Nimodipine
Antihypertensive Agents
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Vasodilator Agents